1. 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. (25th April 2018) Authors: McInnes, Iain; Mease, Philip; Reich, Kristian; Nash, Peter; Andersson, Mats; Abrams, Ken; Pricop, Luminita; Fox, Todd Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. (25th January 2023) Authors: Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A plaidoyer for the use of human skin xenotransplant mouse models in preclinical psoriasis research. (20th October 2022) Authors: Gilhar, Amos; Reich, Kristian; Keren, Aviad; Paus, Ralf Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 37:Number 3(2023) Page Start: e406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patients. (November 2016) Authors: Westphal, Götz A.; Rihs, Hans‐Peter; Schaffranek, Antje; Zeiler, Thomas; Werfel, Thomas; Heratizadeh, Annice; Dickel, Heinrich; Weisshaar, Elke; Bauer, Andrea; Schliemann, Sibylle; Reich, Kristian; Breuer, Kristine; Schröder‐Kraft, Claudia; Worm, Margitta; Molin, Sonja; Brans, Richard; Schäkel, K... Journal: Contact dermatitis Issue: Volume 75:Number 5(2016) Page Start: 303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Issue 10372 (21st January 2023) Authors: Guttman-Yassky, Emma; Simpson, Eric L; Reich, Kristian; Kabashima, Kenji; Igawa, Ken; Suzuki, Tetsuya; Mano, Hirotaka; Matsui, Takeshi; Esfandiari, Ehsanollah; Furue, Masutaka Journal: Lancet Issue: Volume 401:Issue 10372(2023) Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10068 (4th February 2017) Authors: Warren, Richard B; Mrowietz, Ulrich; von Kiedrowski, Ralph; Niesmann, Johannes; Wilsmann-Theis, Dagmar; Ghoreschi, Kamran; Zschocke, Ina; Falk, Thomas M; Blödorn-Schlicht, Norbert; Reich, Kristian Journal: Lancet Issue: Volume 389:Issue 10068(2017) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Arzneimittelsicherheit bei Psoriasis: Welche Rolle spielt Suizidalität?. (March 2017) Authors: Reich, Kristian; Augustin, Matthias Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 15:Number 3(2017) Page Start: 353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Arzneimittelversorgung von Kindern mit Psoriasis in Deutschland. (25th July 2013) Authors: Augustin, Matthias; Reich, Kristian; Glaeske, Gerd; Kämpfe, Susann; Radtke, Marc Alexander; Gerdau‐Heitmann, Cornelia; Schicktanz, Christel; Schäfer, Ines Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 11:Number 8(2013) Page Start: 751 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Issue 10273 (6th February 2021) Authors: Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021) Authors: Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗